A Stroke Case Associated with Tibolone Intake in a Male-to-Female Transgender Patient: A Case Report and Review of Literature
Ahmet Akpınar
, Irmak Salt, Kadriye İrem Carus, Işıl Kalyoncu Aslan, Leyla Ramazanoğlu, Eren Gözke
University of Health Sciences Turkey, Fatih Sultan Mehmet Training and Research Hospital, Clinic of Neurology, Istanbul, Turkey
Keywords: Stroke, ischemic stroke, tibolone, transgender individuals, IV thrombolysis, hormone replacement therapies
Abstract
Hormone replacement therapies (HRT) are known to increase the incidence of thromboembolic events. HRT-related thromboembolic events are mainly related to the estrogen dosage and route of administration. Necessary dosage in transgender individuals is higher than those in postmenopausal women. Tibolone is a specific drug, which has estrogenic, progesterogenic, and androgenic properties and is used in HRT. Many studies reported its effect on the incidence of thromboembolic events in postmenopausal women; however, studies on the possible complications of higher dosage in transgender patients are limited. Therefore, transdermal therapies should be considered due to lower incidence of complications, especially in patients with risk factors for thromboembolic events. Necessary detailed information about the possible complications should be addressed and patients should be followed up closely.
Consent was taken from the patient for publication.
Externally and internally peer-reviewed.
Surgical and Medical Practices: A.A., K.İ.C., I.K.A., Concept: E.G., Design: I.S., E.G., Data Collection or Processing: I.S., K.İ.C., Analysis or Interpretation: A.A., Literature Search: A.A., L.R., Writing: A.A.
No conflict of interest was declared by the authors.
The authors declared that this study received no financial support.